Atul C Pande

US Patent:

6359005, Mar 19, 2002

Filed:

Apr 13, 2001

Appl. No.:

09/807484

Inventors:

Atul Chandra Pande - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 31195

US Classification:

514561, 514567

Abstract:

This invention relates to the use of pregabalin and derivatives thereof for use in the treatment of mania and bipolar disorder.

US Patent:

7026332, Apr 11, 2006

Filed:

Apr 25, 2002

Appl. No.:

10/133471

Inventors:

Cathryn M. Clary - New York NY, US
Jeroen Van Beek - Ridgefield CT, US
Perry S. Eisman - Southampton NY, US
Sean Donevan - Dexter MI, US
Atul Pande - East Lyme CT, US
Richard Kavoussi - Ann Arbor MI, US

Assignee:

Indevus Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 31/4375

US Classification:

514300

Abstract:

Methods of treating obsessive-compulsive disorder comprising administering -(-chloro--naphthyridin--yl)--(-methyl--oxo-hexyl)--isoindolinone are disclosed.

US Patent:

7553847, Jun 30, 2009

Filed:

Feb 13, 2006

Appl. No.:

11/352286

Inventors:

Cathryn M. Clary - New York NY, US
Jeroen Van Beek - Ridgefield CT, US
Perry S. Eisman - Southamton NY, US
Sean Donevan - Dexter MI, US
Atul Pande - East Lyme CT, US
Richard Kavoussi - Ann Arbor MI, US

Assignee:

Indevus Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 31/4745

US Classification:

514300

Abstract:

The present invention provides methods for treating social anxiety disorder, comprising administering 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone or 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-5-hydroxy-2-oxohexyl) -1-isoindolinone or pharmaceutically acceptable salt, or optical isomer therof, and optionally comprising administering another compound for the treatment of social anxiety disorder that is a GABA agonist.

US Patent:

20050059654, Mar 17, 2005

Filed:

Sep 8, 2004

Appl. No.:

10/935826

Inventors:

Stephen Arneric - Milan MI, US
Cathryn Clary - New York NY, US
Douglas Feltner - Novi MI, US
Wilma Harrison - Harrison NY, US
Richard Kavoussi - Ann Arbor MI, US
Atul Pande - East Lyme CT, US
Charles Taylor - Chelsea MI, US

International Classification:

A61K031/519
A61K031/195

US Classification:

514220000, 514259410, 514561000

Abstract:

A method is provided of treating depression in mammals, including a human, as well as depression and a concomitant disease, disorder or condition exemplified by, but not limited to, anxiety, sleep disorder and post-traumatic stress disorder. The method comprises administering to the mammal in effective amount a combination of active ingredients comprising a) an alpha-2delta (A2D) ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and, active agents selected from; (b) a selective serotonin re-uptake inhibitor (SSRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) a selective noradrenaline re-uptake inhibitor (SNRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said prodrug and mixtures of (b) and (c). A pharmaceutical composition comprising a therapeutically effective amount (a) an A2D ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and active agents selected from; (b) an SSRI or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) an SNRI or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said prodrug and mixtures of (b) and (c) is also provided. Preferred active ingredients for the treatment and the pharmaceutical composition include pregabalin, gabapentin, sertraline and reboxetine.

US Patent:

20080280983, Nov 13, 2008

Filed:

May 8, 2008

Appl. No.:

12/117586

Inventors:

Ranga Krishnan - Chapel Hill NC, US
Atul Pande - Cary NC, US

Assignee:

CeNeRx BioPharma - Cary NC

International Classification:

A61K 31/197
A61P 25/00

US Classification:

514563

Abstract:

The present embodiments relate to methods for the treatment of Rett Syndrome. More specifically, the present embodiments relate to pivagabine for use in the treatment of Rett Syndrome. Some embodiments relate to treatment of a patient with Rett Syndrome. Other embodiments relate to treatment of the indications of Rett Syndrome.

US Patent:

55103812, Apr 23, 1996

Filed:

May 15, 1995

Appl. No.:

8/440570

Inventors:

Atul C. Pande - Ann Arbor MI

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 31195
A61K 31215

US Classification:

514561

Abstract:

The present invention is a novel therapeutic use of gabapentin, its derivatives, and the pharmaceutical salts thereof. The compounds are useful in the treatment of mania in all its various forms whether acute or chronic, single or recurrent, and whether or not it is associated with depression. The invention further includes the treatment of bipolar disorder.